Role of probiotics in patients with colorectal cancer: a systematic review protocol of randomised controlled trial studies

Ifeoma Julieth Dikeocha, Abdelkodose Mohammed Al-Kabisi, Salasawati Hussin, Mohammed Abdullah Alshawsh

ABSTRACT
Introduction Colorectal cancer is one of the leading causes of cancer-related morbidity worldwide and it has been reported to be associated with poor lifestyle habits which include excess tobacco and alcohol intake as well as genetics and age factors. Probiotics such as the lactic acid bacteria and Bifidobacterium as well as probiotic containing foods (kombucha, kefir, miso etc) have received lots of attention as anticancer agents for prevention and treatment. The effects of the administration of probiotics to patients with colorectal cancer is the primary goal of this systematic review. The overall aim is to assess how the use of probiotics in patients with colorectal cancer helps in the management of colorectal cancer and its effect on the diversity of gut microbiota. The final systematic review will provide a comprehensive evidence base for the use and efficacy of probiotics in patients with colorectal cancer care.

Methods and analysis The systematic review, will be conducted by extensively searching different databases such as PubMed, Web of Science, Scopus, Wiley and ProQuest to identify randomised controlled trials (with no time frame) which relate to the administration of probiotics to patients with colorectal cancer. The search strategy will include words like colorectal cancer, probiotics, Bifidobacterium, clinical trials etc. A systematic search of databases was performed between 17 and 20 January 2020. Two reviewers will independently review the studies and also search the reference lists of the eligible studies to obtain more references. Data will be extracted from the eligible studies using standardised data extraction form. After assessing the risk of bias, qualitative analysis will be used to synthesise the systematic review.

Ethics and dissemination This is a protocol for a systematic review; therefore, it doesn’t require any ethics approval. We intend to disseminate the protocol in a peer reviewed journal.

INTRODUCTION
Colorectal cancer (CRC) refers to tumours that start in the colon and spread all the way to the rectum. Different types of colorectal polyps exist, but CRC usually develops from adenomas. CRC is one of the very common causes of mortality among patients with cancer worldwide including developed and undeveloped countries but mostly in first world countries. It is predicted that by 2035, over 25 million incidences of CRC will be discovered on a yearly basis. It is also estimated that over 376,000 new cases of CRC diagnosis as well as approximately 200,000 deaths take place yearly in China.

CRC proves to be a silent killer ailment that may not be noticed in time until the cancer has progressed significantly. Symptoms of CRC resemble symptoms of several ailments and is easily misdiagnosed unless a colonoscopy is done. The symptoms of CRC include unexplained anaemia, unexplained weight loss, bloating, changes in the bowel movement habits, bloody stool, vomiting and pelvic pain. It has been proven that the initiating events of CRC include TP53 mutation in CRC associated with colitis as well as mutation in sporadic CRC. Different causes of CRC have been examined over the years from data collected in cohort-based studies and these findings resemble studies carried out in
animal models. The common conclusion is that age, lifestyle choices such as smoking and excessive alcohol intake which can lead to obesity or diabetes, as well as genetic risk factors, contribute to the development of CRC. 

CRC can also be inherited through the genes by inheriting mutated genes that trigger tumour growth, but this only accounts for about 5% of CRC cases. In addition, different researchers in their studies have agreed that an increased number of opportunistic bacteria which quickly turn pathogenic, such as Helicobacter pylori, Bacteroides fragilis, Helicobacter hepaticus, enterotoxigenic Escherichia coli, Fusobacterium nucleatum and Streptococcus bovis, can lead to the initiation of adenomas formation that lead to CRC.

Patients with CRC usually undergo surgery to remove cancerous polyps or to remove some part of their colon which have been affected (colon resection). Others undergo chemotherapy or radiotherapy to treat CRC. These treatment options are sometimes unsuccessful or lead to a myriad of severe side effects which increase hospital stay time and sometimes morbidity. 

Probiotics are redefined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as ‘live microorganisms which when administered in adequate amounts, confer a health benefit on the host.’ Probiotic microorganisms are special because they are capable of surviving in the human gastrointestinal tract before they get to the colon, where the majority of their metabolic activity is carried out. They include lactic acid producing bacteria of the genera Lactobacillus and Bifidobacterium as well as Propionibacterium, Saccharomyces and are the major ingredients in yoghurts and other functional foods such as unfermented milks, cheese, kefir and fermented milk.

On the other hand, prebiotics are usually termed as non-digestible carbohydrates such as inulin and oligosaccharides, soy and resistant starch. Prebiotics is defined by ISAPP as ‘a substrate that is selectively used by host microorganisms to confer health benefit to the host.’ Prebiotic microorganisms are special because they are capable of surviving in the human gastrointestinal tract before they get to the colon, where the majority of their metabolic activity is carried out. They include lactic acid producing bacteria of the genera Lactobacillus and Bifidobacterium as well as Propionibacterium, Saccharomyces and are the major ingredients in yoghurts and other functional foods such as unfermented milks, cheese, kefir and fermented milk.

On the other hand, prebiotics are usually termed as non-digestible carbohydrates such as inulin and oligosaccharides, soy and resistant starch. Prebiotics is defined by ISAPP as ‘a substrate that is selectively used by host microorganisms to confer health benefit to the host.’ Prebiotic microorganisms are special because they are capable of surviving in the human gastrointestinal tract before they get to the colon, where the majority of their metabolic activity is carried out. They include lactic acid producing bacteria of the genera Lactobacillus and Bifidobacterium as well as Propionibacterium, Saccharomyces and are the major ingredients in yoghurts and other functional foods such as unfermented milks, cheese, kefir and fermented milk.

On the other hand, prebiotics are usually termed as non-digestible carbohydrates such as inulin and oligosaccharides, soy and resistant starch. Prebiotics is defined by ISAPP as ‘a substrate that is selectively used by host microorganisms to confer health benefit to the host.’ Prebiotic microorganisms are special because they are capable of surviving in the human gastrointestinal tract before they get to the colon, where the majority of their metabolic activity is carried out. They include lactic acid producing bacteria of the genera Lactobacillus and Bifidobacterium as well as Propionibacterium, Saccharomyces and are the major ingredients in yoghurts and other functional foods such as unfermented milks, cheese, kefir and fermented milk.

On the other hand, prebiotics are usually termed as non-digestible carbohydrates such as inulin and oligosaccharides, soy and resistant starch. Prebiotics is defined by ISAPP as ‘a substrate that is selectively used by host microorganisms to confer health benefit to the host.’ Prebiotic microorganisms are special because they are capable of surviving in the human gastrointestinal tract before they get to the colon, where the majority of their metabolic activity is carried out. They include lactic acid producing bacteria of the genera Lactobacillus and Bifidobacterium as well as Propionibacterium, Saccharomyces and are the major ingredients in yoghurts and other functional foods such as unfermented milks, cheese, kefir and fermented milk.

Probiotics have been used by the traditional healers for the prevention and treatment of different types of illnesses from the simple stomach ache to intestinal neoplasia. In addition various experimental studies have shown that continuous ingestion of probiotic bacteria can enhance the qualitative as well as quantitative components of the gut microbiota.

In one instance, the ingestion of Lactobacillus acidophilus LA-11, L. plantarum CCMCC 1258 and Bifidobacterium longum BL-88 (2.6x1014 (CFU)/day) for 16 days, resulted in an increase in the diversification of gut microflora and microbial richness in patients suffering from CRC who have been scheduled for colorectomy. Eventually, the microbial flora makeup of these individuals improved to resemble that of individuals without CRC. Probiotic bacteria when consumed in adequate quantities are able to diminish the total quantity of non beneficial disease causing bacteria found in the colon by numerous mechanisms, particularly as regards; rivalry for nutrients, growth factors, and adhesion of the probiotics onto the intestinal cells of the host. Ingestion of probiotic also inhibits the activity of pathobionts such as Clostridium perfringens and Klebsiella pneumonia which are potential pathogenic microorganisms and could also be symbiotic microorganisms under certain gut environment conditions. Some probiotic bacteria can produce antibacterial substances such as bacteriocins, hydrogen peroxide, lactic acid and reuterin, which decrease the growth or totally eradicate pathogenic bacteria from the colon. The very popular advantages of the consumption and use of probiotics in the management and treatment of diarrhoea associated to anti-cancer chemotherapy revolves around the restoration to normal of the intestinal microbiota.

The favourable alteration by probiotic bacteria in the makeup of the gut microbiome is closely associated with the reduced risk of suffering from CRC in the future. Production of short chain fatty acids by probiotics which leads to cell apoptosis is one of the aways through which probiotics reduce the proliferation of colorectal carcinoma. Scientific evidence by various in-vitro and in-vivo studies have concluded that various strains of probiotics possess anti-carcinogenic properties via different mechanisms.

Based on our search on systematic reviews related to our topic, we found out that most of the systematic reviews which have been done were not entirely specific to CRC, and those that are specific to probiotics and patients with CRC focus on one outcome either on post-operative complications, surgical site infection, diarrhoea from chemotherapy. We see this as a limitation of these studies, hence we intend to study more than one outcome in order to get a holistic idea of how probiotics administration affect patients with CRC who are receiving different types of treatment on different levels. As we will asses several outcomes, these outcomes will be categorised and discussed based on if they are primary or secondary outcomes. Previously published reviews related to probiotics mostly investigated its effect on CRC and the mechanisms through which probiotics ameliorate CRC using diverse models including pre-clinical studies, and in-vitro studies. Some reviews also focused more on the use of specific probiotic as anticancer adjuvant.

Our systematic review is unique and different from other reviews in which we intend to include only randomised clinical trial studies (RCT) and assess the effects of the administration of various types of probiotics on patients with CRC.
Review aim
To systematically review, assess and summarise and interpret clinical trials studies on how the use of probiotics compared with placebo in patients with CRC in helps in the treatment, and management of CRC. In addition, this study will critically summarise how probiotics administration in patients with CRC affect the diversity of gut microbiome and patient quality of life.

METHODS AND ANALYSIS
This systematic review protocol goes in accordance to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines.

Eligibility criteria for included studies
The inclusion criteria include studies on patients with CRC who are treated with chemotherapy, radiotherapy or surgery. The included studies must be carried out as randomised controlled trials with either a comparator group, control group or placebo group. Details of the inclusion and exclusion criteria that will be used in the systematic review is in table 1.

Search strategy
The relevant studies will be identified using standard search terms for individual databases. Randomised controlled trials will be identified from PubMed, Web of Science, Scopus, Wiley and ProQuest. The search results will be filtered to identify studies only in English. The bibliography of all included randomised controlled trials will be reviewed to identify any trials missed during the initial database search. This will be done independently by two reviewers. Search terms will be used and connected by Boolean AND/OR operators:

Table 1  Eligibility criteria based on PICOS model
<table>
<thead>
<tr>
<th>PICOS model</th>
<th>Eligibility criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Population or participants and conditions of interest</td>
<td>Humans, any age, diagnosed with colorectal cancer (CRC) or with colon cancer or rectal cancer and have been treated with probiotics as an intervention and this will include: Patients with CRC who have had colorectal surgery or colon resection or haven’t had surgery. Patients with CRC who had or are still undergoing chemotherapy or radiotherapy or not.</td>
</tr>
<tr>
<td>2. Interventions or exposures</td>
<td>Probiotics of any kind (eg, Lactobacillus, Bifidobacterium, Propionibacterium, Saccharomyces, etc) used on its own or in combination with other probiotics or combination with prebiotics such as inulin or resistant starch.</td>
</tr>
<tr>
<td>3. Comparisons or control groups</td>
<td>Placebos, or healthy people of any age, without CRC. Baseline comparison of patients before the intervention.</td>
</tr>
<tr>
<td>4. Outcomes of interest</td>
<td>Primary outcomes</td>
</tr>
<tr>
<td></td>
<td>▶ Effects of probiotics on the diversity of human gut microbiota.</td>
</tr>
<tr>
<td></td>
<td>▶ Effects of probiotics on inflammatory biomarkers relevant to CRC.</td>
</tr>
<tr>
<td></td>
<td>▶ Immunoregulatory action of probiotics.</td>
</tr>
<tr>
<td></td>
<td>Secondary outcomes</td>
</tr>
<tr>
<td></td>
<td>▶ Patient status (improvement/ no improvement of colorectal carcinoma) after administration of probiotics.</td>
</tr>
<tr>
<td></td>
<td>▶ Prognosis such as imaging to compare the size of cancer tumour before and after intervention.</td>
</tr>
<tr>
<td></td>
<td>▶ General health and improvement in quality of life of the patient.</td>
</tr>
<tr>
<td></td>
<td>▶ Adverse events such as morbidity and mortality.</td>
</tr>
<tr>
<td>5. Study designs</td>
<td>Clinical trials, randomised clinical trials.</td>
</tr>
<tr>
<td>6. Other exclusion criteria</td>
<td>Articles not in English language.</td>
</tr>
<tr>
<td></td>
<td>Reviews.</td>
</tr>
<tr>
<td></td>
<td>Animal or in vitro work done with zprobiotics.</td>
</tr>
<tr>
<td></td>
<td>Studies not about CRC or rectal cancer.</td>
</tr>
<tr>
<td></td>
<td>Studies not testing the role of probiotics on CRC or rectal or colon cancer patients.</td>
</tr>
</tbody>
</table>

PICOS model, P – Patient, Problem or Population
I – Intervention
C – Comparison, control or comparator
O – Outcome of interest
S – Study type.
The search syntax for PubMed will include:
1. Probiotic* OR Lactobacillus OR Bifidobacterium OR Propionibacterium OR Saccharomyces OR “Bacillus coagulans”.
2. colon OR colorectal OR colonic OR rectal.
3. cancer OR neopla* OR tumor* OR carcinoma OR malignan*.
4. clinical trial OR trial* OR “intervention study” OR RCT OR “randomized controlled trial” OR “randomised controlled trial”.
5. #2 AND #3.
6. #1 AND #4 AND #5.

The search syntax for other databases will be using similar approach as PubMed or using the following merged search terms:
(Probiotic OR Lactobacillus OR Bifidobacterium OR Propionibacterium OR Saccharomyces OR “Bacillus coagulans”) AND (colorectal OR colorectal OR colonic OR rectal) AND (cancer OR neopla* OR tumor* OR carcinoma OR malignan*) AND (“clinical trial” OR “intervention study” OR “RCT” OR “randomised controlled trial” OR “randomized controlled trial”)

A systematic search of PubMed, Scopus, Web of Science, ProQuest and Wiley online library was performed between 17 and 20 January 2020.

Selection process of included studies
The primary article screening will be carried out independently by two reviewers. Titles and abstract of the studies will be screened independently, and the selected studies will be divided into three groups: relevant, irrelevant and unsure. The studies which are categorised as irrelevant by both reviewers will then be eliminated from the review. The full text of the remaining studies will be then reviewed by both reviewers using the eligibility criteria and studies that meet all the criteria will be included. In case of discrepancy, the two reviewers will first meet to discuss their choices and a final decision will be made. If there is any misunderstanding or conflict a third opinion will be sought from the other reviewers and when an agreement is reached, a final decision will be made.

Data extraction and analysis
Studies meeting the inclusion criteria will be processed for data extraction. Two authors (IJD and MAA) will independently screen title and abstract, and then full text. The data will be extracted and recorded in a consistent way using standardised data extraction form. The following data will be extracted: study year, author/s, study title, number of participants, stage of CRC, type of probiotic used, dosage of intervention, duration of intervention, control or placebo used, primary outcomes, secondary outcomes, conclusion and limitation.

The search and study framework will be represented using PRISMA flow chart and the numbers of all included and excluded studies will be reported and the reasons for exclusion of studies will be given.

Assessment of risk of bias of included studies
The risk of bias will be assessed according to the guidelines of the Cochrane Collaboration using ROB tool. This tool will be based on the following domains: random sequence generation, allocation concealment, adequacy of blinding for participants, blinding of outcome assessment, incomplete outcome data and selective reporting and other sources of bias. RoB 2.0 will be used for risk of bias assessment of included study via RevMan V.5.3 software. Two reviewers independently will carry out the assessment and if there is any conflict, third opinion will be obtained from third partner.

Strategy for data synthesis
Initial screening of the relevant RCT studies showed that most of the outcomes of the included studies are not homogenous and cannot be pooled together, therefore meta-analysis most likely will not be carried out. Instead, a qualitative analysis will be performed to synthesise the studies included in the systematic review as well as a critical appraisal of the outcomes will be considered for all studies. However, after we complete the data extraction of all included studies if we find out that any of the outcomes is homogenous across some of the studies, then a meta-analysis of those selected outcomes will be carried out. The quality of all included studies will be assessed by using PRISMA checklist to ensure that the included studies are of good quality and ensure that there is no publication bias.

Patients and public involvement
There will be no need to involve patients or members of the general public in the design of this systematic review, and no patients or member of the public will be contacted in order to complete the systematic review.

Ethics and dissemination
Findings of this systematic review will be published in a peer-reviewed publication and will be presented at a professional conference. Because this is only a protocol, no ethical assessment is required.

Contributors IJD and MAA contributed to the conception of the study. The systematic review protocol was drafted by IJD and was reviewed by MAA and AMA-K. The search strategy was developed by IJD and MAA and will be performed by IJD and MAA, who will also independently screen the potential studies, extract data from the included studies, assess the risk of bias, and complete the data synthesis. AMA-K and SH will arbitrate in cases of disagreement and ensure the absence of errors. All authors reviewed and approved the publication of the protocol.

Funding This study was supported by a research grant from University of Malaya, project number (ST015-2020).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID IDs
Ifeoma Juliet Dikeocha http://orcid.org/0000-0003-1700-828X
Mohammed Abdullah Alshawsh http://orcid.org/0000-0001-8342-5183

REFERENCES